NYSE MKT LLC · PLX
0.00% · $0.0000 · Vol Not reported
Market closed · last close shown
Protalix Biotherapeutics Inc

Protalix Biotherapeutics Inc

Biotechnology
$2.75
Card
Relationship Map

Follow $PLX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $PLX by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measuredMethodology
PLX
Protalix Biotherapeutics Inc
Mon Sep 21 · last completed session · Pre-market · regular session opens 9:30 ET
Highest qualified

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

84/ 100
Veridion Score
Highest qualified · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Mon Sep 21 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is PLX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading PLX catalysts
About Protalix Biotherapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
1996
Employees
226
Country
US

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.75
Last session
Day high
$2.75
Last session
Day low
$2.75
Last session
Previous close
$2.75
52W high
$3.15
-12.70% from high
52W low
$1.67
73% of range
Market cap
$221.6M
P/E
11.00×
EPS
$0.2500
Beta
0.47
Shares out
80.6M
Avg volume
804.4K
VWAP
$2.75
Last session
Price history computed in-house
1W
+3.38%
1M
+15.55%
3M
+22.77%
1Y
+34.80%
YTD
+52.78%
SMA 50 $2.47 · above
SMA 200 $2.29 · above
52W position 73%

PLX overview

Veridion Score
84
Registered · 2026-09-21
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around PLX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading PLX Form 4 filings
Public disclosures

Congress activity in PLX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for PLX in the cached public ledger.

Federal contracts

PLX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for PLX in this window.
Lobbying spend

PLX lobbying filings, year to date.

Registered lobbying filings matched to Protalix Biotherapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for PLX in this window.
Loading news for PLX
Analyst ratings
Sovereign unlock shows live analyst consensus for PLX.
Options
Sovereign unlock shows live options positioning for PLX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.